Experienced in Necrosis

Tatsuya Koike

Hirano-honmachi, JP 
Experienced in Necrosis
Hirano-honmachi, JP 
OverviewLocationsClinical Research

Overview

Tatsuya Koike practices in Hirano-honmachi, Japan. Mr. Koike is rated as an Experienced expert by MediFind in the treatment of Necrosis. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Synovitis, and Osteoporosis.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Necrosis.

Gender
Male

Locations

Hirano-honmachi, 5470044, Japan
Other Locations
Osaka, Japan
Shirahama, Japan
Wakayama, 6492211, Japan
Asahimachi, 5458585, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3

62 Total Publications

Biological/targeted synthetic disease-modifying antirheumatic drugs improve not only muscle mass but also phase angle in patients with rheumatoid arthritis.
Biological/targeted synthetic disease-modifying antirheumatic drugs improve not only muscle mass but also phase angle in patients with rheumatoid arthritis.
Journal: Clinical rheumatology
Published: August 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Koike's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile